Tuesday, 24 April 2012

BioLargo (BLGO): An Important Play on Wound Care - Article Published by SECFilings.com

Published Tuesday, April 24, 2012 by Ryan Allway

BioLargo Inc. (OTCBB: BLGO), a company focused on leveraging Nature’s Best Solution® - iodine– to solve a variety of common problems around the world, operating in industries dominated by giants such as Chemtura Corp (NYSE: CHMT) and Polypore International Inc. (NYSE: PPO), also looks to have an important and potentially significant play in the wound management industry which should bode well for its commercial prospects.

In a recent blog post, BioLargo elaborated on this potential:

With the cost of chronic wound care rising, efforts are underway to improve prevention, early detection and treatment,
as WSJ reports in today’s special report on innovation in health care. That’s good news for the makers of wound-care products: Research firm Kalorama Information projects the global market will rise to nearly $21 billion in 2015 from $16.8 billion this year.

The National Institute of Health also published a comprehensive report entitled, “Human Skin Wounds: A Major and Snowballing Threat to Public Health and the Economy”, which points out that close to seven million Americans suffer from chronic wounds and more than $25 billion is spent annually on their care. Wound care is big business and, as these reports indicate, it is getting bigger.

So, why is BioLargo likely to become an important player in this industry?

Reportlinker.com issued a comprehensive report early this year, Innovations in Wound Care Devices and Dressings is quoted, “Significant areas of development in the advanced wound dressing segment are within the areas of antimicrobials (silver, iodine, and honey) hydrocolloids and hydrogels. “ Pointing out the increasing focus by industry on iodine and similar technologies.

BioLargo has developed unique iodine solutions aimed to source and deliver “free-iodine” on demand. The company’s CupriDyne® solution works by combining minerals with water from any source to deliver “free-iodine” in controlled dosages, in order to balance efficacy of disinfectant or odor control performance with concerns about toxicity. It appears to offer numerous advantages to traditional iodine in that its environmentally-friendly products are both safe and effective, but still non-toxic and non-staining. BioLargo’s technology looks to be a perfect fit for the healthcare market, just as that industry is turning toward iodine, hydrocolloids and hydrogels that are safe and effective while helping avoid microbial resistance as iodine is known to do.

BioLargo’s future in wound care looks to be both important and significant.

Monday, 23 April 2012

Iodine Deficiency in India is Alarming- The Times of India Reports- Bid to Eradicate IDD Points to BioLargo Opportunity

NEW DELHI: India has stepped up its efforts to stamp out the use of non-iodized salt. The Mission Steering Group (MSG) - the highest decision-making body of the National Rural Health Mission (NRHM) headed by Union health minister Ghulam Nabi Azad - passed a resolution on Monday to pay Rs 300 to each ASHA annually on testing of at least 50 salt samples per month for 303 iodine deficiency-endemic districts.

According to the health ministry, only 20 lakh metric tonnes of iodated salt in the country is being sold in packets. The rest is sold as loose salt. To make matters worse, even labeled salt packets have been found to be non-iodized.

Experts say iodine is one of the most essential micronutrients with an average daily requirement of 100-150 micrograms for normal human growth and development. At present, no state in the country is free from Iodine Deficiency Disorders (IDD).

Under the NRHM, each ASHA will be given 10-12 kits for a year. A drop of a special solution on the salt from a plastic vial brings about a colour change showing the presence of iodine. The intensity of colour change also indicates the level of iodine present in the salt. These kits will be highly useful in the field as they do not require any infrastructure and are inexpensive, sensitive and will provide immediate results.

The MSG meeting document says, "ASHA being from the same community/village would be very helpful in determining the quality of salt available in the village and will be in position to motivate the people to reject the use of non-iodated salt. She will report to the panchayats which will generate action to compel retail shops to sell iodated salt only. It is proposed that ASHA would be paid an honorarium of Rs 25 per month for testing at least 50 salt samples every month, which works out to 50 paisa per salt sample testing."

In India, 71 million people are suffering from IDD, which is the leading cause for mental retardation worldwide. Every year 13 million children are born in India unprotected from brain damage caused by iodine deficiency. It is estimated that 200 million population people in India are exposed to the risk of IDD.

The health ministry data says that out of 324 districts in all the 28 states, 263 districts are endemic, where the prevalence of IDD is more than 10%. Under the 12th Plan, India aims to bring down prevalence of IDD below 5% in the entire country. By 2017, the ministry wants to ensure 100% consumption of adequately iodated salt (15 PPM) at the household level.

The MSG said that according to the National Family Health Survey (NFHS-III), consumption of adequately iodated salt at the household level is only 51%. The consumption of adequately iodated salt at the household level in below poverty line and SC/ST population is about 30% and 40%, respectively. This indicates that the household of BPL and SC/ST population consuming nil/inadequate iodated salt as about 70% and 60%, respectively.

Iodometric titration, the traditional method for determining iodine content, is an accurate method, but it is time-consuming and requires infrastructure and trained personnel. In India, these laboratories are located at the state headquarters. Hence, the length of time between collecting the sample and the availability of results is considerably high.

"It is important that salt monitoring is carried out at community level so that the people themselves are in a position to demand iodized salt. This is all the more important for areas where loose salt is being used and labels cannot be an indication of iodations of salt. The scheme is expected to cost Rs. 12.27 crore per annum," MSG said.

Low Iodine in Women of Childbearing Age- As reported by BabyMed referencing a CDC study all point to BioLargo Opportunity

Low Iodine In Women Of Childbearing Age

By Dr.Amos
04/19/2012 3:13 PM
The CDC (Centers for DiseaseControl) have reported that iodine levels in women of childbearing age are lower than expected and possibly lower than they should be for optimal health. According to the report released by the CDC, women between the ages of 20 and 39 have low iodine levels, sometimes bordering on iodine deficiency. The body needs iodine for essential functions like growth and development. Iodine is also required for thyroid health.

Low Iodine Thyroid Pregnancy

If iodine levels remain lower than the body needs for basic functions, mental development and thyroid function can be depressed. Goiter, cretinism and hypothyroidism are all associated with low iodine levels in men and women.

What’s interesting about the CDC report is the fact that the main source of iodine in more than 70 countries is table salt with added iodine. Dairy, eggs and grains also contain high levels of iodine, but not to the level of table salt.Fruits and vegetables also contain iodine, but the total amount is determined by the amount of iodine in the soil and various factors associated with care while growing, like fertilizer.

In terms of pregnancy, the CDC worries that pregnant women who don’tconsume enough table salt or dairy products may have lower than healthy iodine level, which could affect the pregnancy and growth of the fetus. If a mother is deficient in iodine it can cause mental retardation and growthdepression. The effects on the fetus are long-term and cannot be reversed after birth.

There is a careful line when it comes to consuming enough iodine via table salt. Pregnant women who restrict salt intake should discuss the risk of iodine deficiency with their obstetrician early in pregnancy or, ideally, before pregnancy. Your obstetrician may suggest seeing a nutritionist to properlyplan out how to increase iodine intake without greatly increasing salt intake.

Source: FA Tayie, K Jourdan. CDC, Office of Dietary Supplements, National Institutes of Health. 6 April, 2012.

Friday, 20 April 2012

BioLargo Interview on Sky Radio- Describes Nature's Best Solution® - Free Iodine - the cornerstone of a platform technology that makes life better!

BioLargo President & CEO, Dennis Calvert describes how Nature's Best Solution®- Free Iodine, first discovered by Kenneth Reay Code, has helped build a platform technology that can help make life better!

This is a timeless interview that first aired in 2008 on Sky Radio. While both technical and commercial advancements for BioLargo are substantial since this first airing, the interview provides a succinct synopsis that you might find helpful.

Thursday, 19 April 2012

BioLargo Embarks on Campaign to Promote New Free-Iodine Solution- Article by HealthTech Zone.com

March 27, 2012

Biolargo is the patent-holder of a new, free-iodine-based product called "Nature's Best Solution" that makes some exciting promises. They recently outlined plans to work with several companies in both the commercial and industrial sectors to develop retail products containing their formula.
The company succeeded in developing a particularly pure and potent type of iodine without the toxic side effects company associated with the chemical. This new type of iodine will provide the basis for a new generation of specialized sanitation products that benefit such areas as both human and veterinary medicine, domestic, agricultural, manufacturing, and more. Right now, Biolargo's primary concern is raising awareness of their product among these industries as much as possible.
One of the most exciting aspects about Biolargo's discovery is that it provides an alternative to the traditional anti-bacterial cleaning solutions, the over-use of which has led to the appearance of MRSA, a deadly acute strain of staph bacteria that emerged in the early 1960s.
Not only is MRSA resistant to traditional antibiotic treatments, but what makes it such a specifically profound horror show is this: a significant body of research suggests that the over-use of common anti-bacterial cleaning agents actually produces it. It appears commonly in medical quarters, public housing developments and other areas with a high volume of bodily traffic that are cleaned regularly with strong disinfectants. Nature's Best Solution can provide these environments with disinfecting alternatives. In doing so, it can makes these areas less conducive to producing these types problematic bacteria. Jeanine Thomas, founder of the MRSA Survivors Network, says that without such methods, not only MRSA, but "other infections such as C. difficile and VRE,” will continue to increase.
If the part about hospitals isn't enough to call the hair on the back of your neck to attention, British and Scottish epidemiologists have noticed new strains of MRSA in cow's milk. It makes sense, for this reason, that among other companies, Biolargo is negotiating with Green Alpha Solutions, LLC. A California-based company, Green Alpha wants to design a free-iodine-based cleaning product specialized for use in the dairy industry.

Edited by Tammy Wolf

Tuesday, 17 April 2012

A Burgeoning Market for Wound Care- Wall Street Journal Article Points to BioLargo Opportunity

April 16, 2012, 12:18 PM ET

A Burgeoning Market for Wound Care

With the cost of chronic wound care rising, efforts are underway to improve prevention, early detection and treatment, as WSJ reports in today’s special report on innovation in health care. That’s good news for the makers of wound-care products: Research firm Kalorama Information projects the global market will rise to nearly $21 billion in 2015 from $16.8 billion this year.

Among the products expected to increase in use: negative pressure wound therapy which uses special dressings and vacuum technology to speed healing. London-based GlobalData recently forecast that market will double to $4 billion by 2018 from $2 billion last year, with an increase in the use of single-use disposable devices and portable systems that can be used in home care.

Among the companies set to benefit, according to the research reports: KCI, Smith & Nephew, ConVatec and Johnson & Johnson.

But with a gap in knowledge about the most effective treatments, the federal Agency for Healthcare Research and Quality last year awarded the Johns Hopkins Evidence-based Practice Center a $475,000 grant to review state-of-the-art wound care, determine what’s known about medications, antibiotics, dressings and surgery, and establish strategies of care that are proven to work.

“There is a very limited amount of well-developed information about how you deal with wounds,” co-investigator Dr. Gerald Lazarus tells the Health Blog. A dermatology professor and founder of the wound center at Johns Hopkins Bayview Medical Center, Lazarus says the focus of the review will be on chronic lower extremity wounds, which can be complications of leg ulcers and diabetes and can be exacerbated by obesity and poor nutrition. But he expects what they learn to be applicable to other types of wounds such as pressure ulcers or bed sores, as well.

Close to seven million Americans suffer from chronic wounds and more than $25 billion is spent annually on their care, according to a 2009 study.

Among the issues that are debated in wound care is the role of antibiotics, which can promote development of resistant organisms in the wounds, and the most appropriate wound dressings, which range widely in price. Expensive oxygen chambers — known as hyperbaric therapy — are good for some kind of wounds, but may not be appropriate for all types, Lazarus says.

“Wounds that will not heal are frequently signs of larger and more complicated health problems, and can take a toll on patients far beyond the pain and discomfort of the wound,” Lazarus says. “We always want to focus on what’s best for the patient but with the runaway situation in health costs, there should be justification that the treatments being used have documented value.”

Copyright 2008 Dow Jones & Company, Inc.

Sunday, 15 April 2012

BioLargo Offers a Solution to Water Pollution in Oil and Gas Industry- OTC Investor Article

BioLargo Offers a Solution to Water Pollution in Oil and Gas Industry

By Andrew Klips · Monday, April 9th, 2012

Contaminated water is a growing concern across North America, especially as related to the oil and gas industry. A December 2011 article posted by staff at the Natural Resources Defense Council highlighted more than 30 reported incidents across 13 U.S. states of drinking water contamination with hydraulic fracturing as the suspected cause. The author emphasized that those listed were only a sampling of reported cases “where a homeowner had enough detailed knowledge to know that a nearby well was recently fractured and specifically included that information in reports.” Cases were reported at wells owned by large publicly-traded companies such as Southwestern Energy Corp. (NYSE: SWN), Ballard Petroleum (now Encana Corporation (NYSE: ECA)), Chesapeake Energy Corp (NYSE: CHK), Devon Energy Corp. (NYSE: DVN) and Range Resources Corp. (NYSE: RRC).

Movie goers that have seen “A Civil Action,” starring John Travolta and Julia Roberts, can imagine that type of lawsuits that are ongoing in those communities claiming damages because hydraulic fracturing has polluted their water. Albeit that movie was about dumping toxic waste, it has a similar undertone as big business is disputing the claims of the residents. Concerned investors and citizens are encouraged to perform their due diligence on pollution and water contamination from hydraulic fracturing and other common practices in the oil and gas industry to better understand the magnitude of the problem.

There is a company that is establishing a growing presence with its ability to offer a solution to the malevolent hydraulic fracturing business. BioLargo, Inc. (OTCBB: BLGO), a creator of patented iodine technologies, has developed CupriDyne™-SAP, a proprietary technology uniquely suited to detoxify water in a variety of applications, including the oil and gas industry. Using Iodine in a stable molecular form, CupriDyne™-SAP is able to eradicate bacteria and sop-up heavy metals and radioactive elements. Iodine, one of nature’s most powerful cleaners, is simply combined with the somewhat ineffective filtration processes that are presently used. The reaction products are harvested; leaving clean water as the end product and eliminating the threats that watersheds, wells and groundwater in the area currently face.

The possibilities for the BioLargo technology are tremendous in the energy sector. Enormous amounts of water are used and/or generated (saline water is extracted from the ground with the oil and gas) every day in collecting oil and gas reserves. The ratio of produced water to oil is roughly 10 barrels of produced water per 1 barrel of oil. According to the American Petroleum Institute, more than 18 billion barrels of waste fluids from oil and gas production are generated annually in the United States. That’s more than two million barrels of tainted water every hour…and that’s just in the U.S.

Energy is an integral part of the Canadian economy. In 2009, the $80.2 billion energy sector represented 6.7% of Canada’s gross domestic product. Canada’s oil sands industry has been put under a microscope in recent years because of its contaminative nature. The oil sands of Northern Alberta are the second largest oil deposits in the world, behind only Saudi Arabia. Because of the way that the oil is trapped in the sands, it takes special processes – and plenty of water – to extract the oil and make it fluid enough to travel through pipelines. In general, three to four barrels of water are used/contaminated for each barrel of oil produced from tar sands.

In June of 2011, the Canadian Association of Petroleum Producers said, “Oil sands growth and new production from existing conventional oil reserves will drive Canadian crude oil production to about 4.7 million barrels per day by 2025.” That means that billions of barrels of polluted water will be generated in the process each year as well.

So what happens with the contaminated water? Theoretically, it is should be processed to ensure that it is non-toxic. According to the U.S. EPA, “Produced waters contain levels of radium and its decay products that are concentrated, but the concentrations vary from site to site. In general, produced waters are re-injected into deep wells or are discharged into non-potable coastal waters.”

Water contamination in the oil and gas industry is a growing concern. As such, people, companies and countries are starting to hone-in on what BioLargo has to offer. That’s why investors should be taking note of its corporate happenings. The company has been appointed as a founding member of a Canada’s Natural Sciences and Engineering Research Council (NSERC) “Industrial Research Chair in Oil Sands Tailings Water Treatment” formed to solve the contaminated water and tailing ponds problems associated with the oil sands industry, leaving the company in a prime position for growth.

“The core technology is well established and with the addition of our world-class team members over the past year, it is now a great time for BioLargo to refine, focus and execute to help solve serious problems that face industry and our world,” said Dennis Calvert, President and CEO of BioLargo in a recent company statement.

The bottom line is that green energy initiatives (i.e. solar, wind) are fantastic in theory and gaining momentum in frequency of use, but still nascent in energy’s big picture. Oil and gas are still going to be the primary sources of energy for the foreseeable future. There are plenty of reserves in North America to accommodate less reliance on foreign oil, but the industry has to transition its processes into having less of an impact on the environment and population. BioLargo holds a key to that evolution.